Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925252 | 1.00 | HTR2C (0.30) | HTR2CHTR2B | |
| SCHEMBL421221 | 0.65 | HSP90AA1 (0.57) | — | |
| SCHEMBL15087182 | 0.64 | HSP90AA1 (0.34) | — | |
| SCHEMBL26581512 | 0.62 | SCN9A (0.45) | — | |
| SCHEMBL13833713 | 0.62 | HSP90AA1 (0.42) | — | |
| SCHEMBL23809469 | 0.56 | CHRNA7 (0.35) | — | |
| SCHEMBL13983493 | 0.55 | KCNK3 (0.43) | — | |
| SCHEMBL6588435 | 0.55 | KDM4E (0.50) | — | |
| SCHEMBL22538729 | 0.54 | NR4A2 (0.49) | — | |
| SCHEMBL23809278 | 0.54 | NR4A2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012162372-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162584-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162293-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012141796-A2 | PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012096919-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2011133521-A2 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133520-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |